Focal segmental glomerulosclerosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
|||
| (17 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Focal segmental glomerulosclerosis}} | {{Focal segmental glomerulosclerosis}} | ||
{{CMG}} | {{CMG}}{{APM}} {{AE}}{{OO}} | ||
==Overview== | ==Overview== | ||
Randomized clinical trials have only addressed patients with primary FSGS and have nephrotic-range proteinuria. For those patients, the use of corticosteroids and immunosuppressive therapy followed by | Treatment of Idiopathic or primary FSGS is very difficult. Treatment should be tailored towards relieving symptoms and preventing disease progression. The use of loop diuretics to manage the edema and corticosteroids to suppress immune function has been successful in some. | ||
However, secondary causes of FSGS are treated by treating the underlying causes. Highly Active Anti-Retroviral Therapy can be used in HIV patients with FSGS. Immunosuppressant like prednisone can be used in immune mediated FSGS. Loop diuretics like furosemide can be used to control the edema and proteinuria. | |||
FSGS patients who progress to End Stage Kidney disease would need lifelong dialysis. | |||
Randomized clinical trials have only addressed patients with primary FSGS and have nephrotic-range proteinuria. For those patients, the use of corticosteroids and immunosuppressive therapy followed by conservative therapy with ACE-I or ARBs is recommended, according to the 2012 KDIGO guidelines.<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408 }} </ref> For patients with relapse, guidelines for relapsing minimal change disease are recommended for patients with FSGS. Finally, patients with resistance to steroids are recommended to use cyclosporine, or a combination of mycophenolate mofetil and high dose dexamethasone for patients who cannot tolerate cyclosporine. | |||
==Medical Therapy== | ==Medical Therapy== | ||
The mainstay of treatment for focal segmental glomerulosclerosis is medical therapy, however dietary therapy is used to control hypertension and proteinuria. | |||
==Dietary therapy== | |||
Dietary therapy is used to control hypertension, edema, and proteinuria, which include: | |||
*Salt intake should be reduced 2 g of sodium per day | |||
*Protein intake should be 1-1.3 g/kg of body weight | |||
*There should be reduction of fat intake | |||
*Daily exercise is important to reduce weight for obese patients | |||
The use of medical therapy in focal segmental glomerulosclerosis (FSGS) is based on the Kidney Disease - Improve Global Outcomes (KDIGO) guidelines of 2012.<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408 }} </ref> | |||
The use of both corticosteroids and immunosuppressive therapy is recommended for initial treatment in patients with idiopathic FSGS and who have nephrotic syndrome. | * Initial Treatment: The use of both corticosteroids and immunosuppressive therapy is recommended for initial treatment in patients with idiopathic FSGS and those who have nephrotic syndrome.<ref name="pmid18065791">{{cite journal| author=Gupta K, Iskandar SS, Daeihagh P, Ratliff HL, Bleyer AJ| title=Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin. | journal=Nephrol Dial Transplant | year= 2008 | volume= 23 | issue= 5 | pages= 1595-9 | pmid=18065791 | doi=10.1093/ndt/gfm833 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18065791 }} </ref> | ||
==== | |||
===Corticosteroids=== | |||
Preferred regimen (1) prednisone : Single dose of 1 mg/kg/d (maximum 80 mg/d) or alternate-day dose of 2 mg/kg (maximum 120 mg) PO for minimum 4 weeks - maximum 16 weeks, as tolerated, or until complete remission is achieved.<ref name="pmid1934660">{{cite journal |vauthors=Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C |title=The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study |journal=Clin. Nephrol. |volume=36 |issue=2 |pages=53–9 |date=August 1991 |pmid=1934660 |doi= |url=}}</ref> | |||
Steroids should be tapered slowly over a period of 6 months after achieving complete remission, ie. reduction in dose by 10 mg per 2 weeks down to 0.15 mg/kg/d, then every 2-4 weeks by 2.5 mg. | |||
Contraindication to the use of steroids: | |||
* Uncontrolled diabetes mellitus | |||
* Psychiatric conditions | |||
* Severe osteoporosis | |||
=== | ====Calcineurin Inhibitors (CNI)==== | ||
For patients with relative contraindication to steroids, such as patients with uncontrolled diabetes mellitus, psychiatric conditions, or severe osteoporosis, the use of CNI might be more helpful.<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408 }} </ref> | |||
===Treatment for Relapse | ===Treatment for Relapse=== | ||
Treatment for relapse is based upon the guidelines for the management of relapse of minimal change disease in adults. | Treatment for relapse is based upon the guidelines for the management of relapse of minimal change disease in adults. | ||
===Treatment for Steroid-Resistant FSGS=== | ===Treatment for Steroid-Resistant FSGS=== | ||
====Cyclosporine<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408 }} </ref>==== | ====Cyclosporine<ref name="pmid23871408">{{cite journal| author=Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH et al.| title=KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. | journal=Am J Kidney Dis | year= 2013 | volume= 62 | issue= 3 | pages= 403-41 | pmid=23871408 | doi=10.1053/j.ajkd.2013.06.002 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23871408 }} </ref>==== | ||
*''Dose'': 3-5 mg/kg/d in divided doses | *''Dose'': 3-5 mg/kg/d in divided doses (initial target: 125-175 ng/ml) | ||
*''Duration'': At least 4-6 months. Cyclosporine therapy is to be continued for at least 12 months only if there is partial or complete remission with use. | *''Duration'': At least 4-6 months. Cyclosporine therapy is to be continued for at least 12 months only if there is partial or complete remission with use. For patients who have not achieved any remission by 6 months, discontinuing cyclosporine is recommended. | ||
Slow tapering of cyclosporine should be achieved following the initial duration of use. Tapering should be a reduction in dose by 25% every 2 months. For patients who cannot tolerate cyclosporine, the use of a combination of mycophenolate mofetil and high-dose dexamethasone is recommended. | |||
====Tacrolimus and Prednisone==== | |||
=====Tacrolimus===== | |||
*''Dose'': 0.1-0.2 mg/kg/d in two divided doses (initial target 5-10 ng/ml) | |||
If remission is achieved, follow cyclosporine recommendations. | |||
=====Prednisone===== | |||
*''Dose'': 0.15 mg/kg/d | |||
*''Duration'': 4-6 months | |||
Prednisone is to be tapered off over 4-8 weeks. | |||
====Other==== | ====Other==== | ||
Latest revision as of 03:02, 25 June 2018
|
Focal segmental glomerulosclerosis Microchapters |
|
Differentiating Focal segmental glomerulosclerosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Focal segmental glomerulosclerosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Focal segmental glomerulosclerosis medical therapy |
|
Focal segmental glomerulosclerosis medical therapy in the news |
|
Directions to Hospitals Treating Focal segmental glomerulosclerosis |
|
Risk calculators and risk factors for Focal segmental glomerulosclerosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3]
Overview
Treatment of Idiopathic or primary FSGS is very difficult. Treatment should be tailored towards relieving symptoms and preventing disease progression. The use of loop diuretics to manage the edema and corticosteroids to suppress immune function has been successful in some. However, secondary causes of FSGS are treated by treating the underlying causes. Highly Active Anti-Retroviral Therapy can be used in HIV patients with FSGS. Immunosuppressant like prednisone can be used in immune mediated FSGS. Loop diuretics like furosemide can be used to control the edema and proteinuria. FSGS patients who progress to End Stage Kidney disease would need lifelong dialysis.
Randomized clinical trials have only addressed patients with primary FSGS and have nephrotic-range proteinuria. For those patients, the use of corticosteroids and immunosuppressive therapy followed by conservative therapy with ACE-I or ARBs is recommended, according to the 2012 KDIGO guidelines.[1] For patients with relapse, guidelines for relapsing minimal change disease are recommended for patients with FSGS. Finally, patients with resistance to steroids are recommended to use cyclosporine, or a combination of mycophenolate mofetil and high dose dexamethasone for patients who cannot tolerate cyclosporine.
Medical Therapy
The mainstay of treatment for focal segmental glomerulosclerosis is medical therapy, however dietary therapy is used to control hypertension and proteinuria.
Dietary therapy
Dietary therapy is used to control hypertension, edema, and proteinuria, which include:
- Salt intake should be reduced 2 g of sodium per day
- Protein intake should be 1-1.3 g/kg of body weight
- There should be reduction of fat intake
- Daily exercise is important to reduce weight for obese patients
The use of medical therapy in focal segmental glomerulosclerosis (FSGS) is based on the Kidney Disease - Improve Global Outcomes (KDIGO) guidelines of 2012.[1]
- Initial Treatment: The use of both corticosteroids and immunosuppressive therapy is recommended for initial treatment in patients with idiopathic FSGS and those who have nephrotic syndrome.[2]
Corticosteroids
Preferred regimen (1) prednisone : Single dose of 1 mg/kg/d (maximum 80 mg/d) or alternate-day dose of 2 mg/kg (maximum 120 mg) PO for minimum 4 weeks - maximum 16 weeks, as tolerated, or until complete remission is achieved.[3]
Steroids should be tapered slowly over a period of 6 months after achieving complete remission, ie. reduction in dose by 10 mg per 2 weeks down to 0.15 mg/kg/d, then every 2-4 weeks by 2.5 mg.
Contraindication to the use of steroids:
- Uncontrolled diabetes mellitus
- Psychiatric conditions
- Severe osteoporosis
Calcineurin Inhibitors (CNI)
For patients with relative contraindication to steroids, such as patients with uncontrolled diabetes mellitus, psychiatric conditions, or severe osteoporosis, the use of CNI might be more helpful.[1]
Treatment for Relapse
Treatment for relapse is based upon the guidelines for the management of relapse of minimal change disease in adults.
Treatment for Steroid-Resistant FSGS
Cyclosporine[1]
- Dose: 3-5 mg/kg/d in divided doses (initial target: 125-175 ng/ml)
- Duration: At least 4-6 months. Cyclosporine therapy is to be continued for at least 12 months only if there is partial or complete remission with use. For patients who have not achieved any remission by 6 months, discontinuing cyclosporine is recommended.
Slow tapering of cyclosporine should be achieved following the initial duration of use. Tapering should be a reduction in dose by 25% every 2 months. For patients who cannot tolerate cyclosporine, the use of a combination of mycophenolate mofetil and high-dose dexamethasone is recommended.
Tacrolimus and Prednisone
Tacrolimus
- Dose: 0.1-0.2 mg/kg/d in two divided doses (initial target 5-10 ng/ml)
If remission is achieved, follow cyclosporine recommendations.
Prednisone
- Dose: 0.15 mg/kg/d
- Duration: 4-6 months
Prednisone is to be tapered off over 4-8 weeks.
Other
For patients who cannot tolerate cyclosporine, the use of a combination of mycophenolate mofetil (MMF) and high-dose dexamethasone is recommended.[1]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH; et al. (2013). "KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis". Am J Kidney Dis. 62 (3): 403–41. doi:10.1053/j.ajkd.2013.06.002. PMID 23871408.
- ↑ Gupta K, Iskandar SS, Daeihagh P, Ratliff HL, Bleyer AJ (2008). "Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin". Nephrol Dial Transplant. 23 (5): 1595–9. doi:10.1093/ndt/gfm833. PMID 18065791.
- ↑ Banfi G, Moriggi M, Sabadini E, Fellin G, D'Amico G, Ponticelli C (August 1991). "The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study". Clin. Nephrol. 36 (2): 53–9. PMID 1934660.